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Abstract 
The development of a continuous-flow process for asymmetric hydrogenation with a heterogenized 
molecular catalyst in a real industrial context is reported. The key asymmetric step in the synthesis of 
an API (active pharmaceutical ingredient) has been developed on a kilogram scale with constant high 
single-pass conversion (>95.0 %) and enantioselectivity (>98.6 % ee) through the asymmetric 
hydrogenation of the corresponding enamide. This performance was achieved using a commercially 
available chiral catalyst (Rh/(S,S)-EthylDuphos) immobilized on a solid support via electrostatic 
interaction. The factors affecting the long term catalyst stability and enantioselectivity were identified 
using small-scale continuous-flow set-ups. A dedicated automated software-controlled high-pressure 
pilot system with a small footprint was then built and the asymmetric hydrogenation on kilogram-scale 
was carried out with a space time yield (STY) of up to 400 gL-1h-1 at pre-defined conversion and 
enantiopurity levels. Most importantly, no catalyst leaching was detected in the virtually metal-free 
product stream, thereby eliminating costly and time-consuming downstream purification procedures. 
This straightforward approach permitted an easy and robust scale-up from gram to kilogram scale fully 
matching the pharmaceutical quality criteria for enantiopurity and low metal content, thus 
demonstrating the high versatility of fully integrated continuous flow molecular catalysis. 
 
Introduction 
Continuous processing has long been recognized as a promising method for process intensification in 
the chemical industry. Although continuous manufacturing has long been common in large scale 
production, it only recently has begun attracting increased attention from the pharmaceutical 
industry.[1] It is now clear that   continuous flow processing can contribute to minimizing costs and 
intensifying production,[2] especially in the production of complex molecules where constant quality 
standards are required and expensive catalyst and/or high pressure are needed.  Small and flexible 
reactor systems can also allow the integration of multiple operations either consecutively or even 
simultaneously,[3] for example the incorporation of continuous workups and product extraction post-
reaction.[4] Both upstream and downstream operations can be integrated into a single process unit 
rather than being separated in space or time, allowing a more efficient process. These technologies 
offer unique scale-up opportunities because of the improved control on mass and heat transfers and 
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the possibility to scale out with relatively small reactor footprints. Such reactor systems can also be 
automated with online analysis allowing for faster optimization and better control of the overall 
performance.[5] 
The advantages of fully integrated continuous flow systems are best exemplified in the context of 
homogeneous catalysis where often additional purification steps are required to remove or potentially 
recycle an expensive organometallic catalyst.[3, 6] The use of solid supported homogeneous catalysts in 
continuous flow is therefore very attractive, because both the reaction and the purification/recycling 
steps can be combined into a single process.[7] The reagents are pumped through a tubular reactor 
containing high concentrations of catalyst, thereby allowing for shorter reaction times and substantial 
process intensification. Highly efficient, solid-supported continuous flow catalysis has yet to be 
adopted in real industrial situations and it is the purpose of this paper to demonstrate its viability in 
an actual application to the pharmaceutical industry.[8] 
Non-covalent immobilization is a promising strategy in solid supported homogeneous catalysis as off-
the-shelf catalysts can be easily dispersed within the stationary phase without need for extensive 
chemical modification.[9] This approach is, in principle, more attractive than the conventional covalent 
immobilization strategies. However, it is  rather more challenging to implement because the catalyst 
has greater potential for leaching  and contaminating the product. We show here that leaching  can be 
reduced and even avoided completely, if electrostatic interactions are exploited to retain ionic 
catalysts within ionic matrices. Our groups have contributed largely to the implementation of such 
heterogenized systems in continuous flow apparatus to simplify and intensify asymmetric 
hydrogenation reactions. Recent examples have involved  the use of ionic liquids (IL)[10] or supported 
ionic liquids (SILP) as stationary phase and supercritical CO2 (scCO2) as the mobile phase.[11] An earlier 
example, developed at Nottingham, was based on the so-called “Augustine approach”[12] in a 
continuous scCO2 process.[13] The Augustine approach uses heteropolyacids which are dispersed on a 
metal oxide surface and serve as anchors for cationic organometallic complexes (Figure 1). The 
attachment is based on a strong electrostatic interaction between the charged metal center and an 
oxygen atom of the heteropolyacid anchor which itself interacts via hydrogen bonding with the 
hydroxyl groups of the metal oxide support.[14] This supramolecular assembly is further entrapped 
inside the pores of the support which, in most cases, enhances stability without altering selectivity. 
Such anchoring systems are now well established as being very robust and efficient in asymmetric 
hydrogenations.[15] Recently, Cole-Hamilton and co-workers used this anchoring method and obtained 
very good results in the continuous flow solvent-free hydrogenation of dibutyl itaconate at low 
pressure.[16] Several other elegant demonstrations in the area of non-covalent immobilization have 
been reported but all of them have used model substrates, e.g. dimethyl itaconate, and have been 
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limited to academic laboratory scales.[9, 17] Until now, however, adapting these modern technologies 
to more demanding substrates in a “real” industrial context has been an unmet challenge.[8] 
This paper now reports how the Augustine immobilization technique can be applied to the synthesis 
of a key intermediate in the synthesis of an API (active pharmaceutical ingredient) and on a 
considerably larger scale than previously attempted. We show that a number of issues associated with 
catalyst stability can be simply solved by combining continuous flow technologies with an appropriate 
reactor system, thereby maximizing catalyst utilization in an optimized operation. Finally, we 
demonstrate an efficient scale-up from gram- to kilogram-scale production in a cost-effective manner 
compared to the original batch process. Moreover, the development of this process has been carried 
out in two different labs, by various operators and with different rig designs thereby demonstrating its 
inherent robustness for pharmaceutical and fine chemical production. The developments described in 
this paper have provided a set of parameters for successful operative conditions and have the potential 
to be adapted to other industrially relevant processes. 
 
Figure 1: Depiction of the Augustine strategy showing anchoring of a molecular catalyst to a solid support via a heteropolyacid 
linker. 
 
Our study has involved API, 1, which is a JAK2 kinase inhibitor previously tested at the clinical level at 
AstraZeneca (Scheme 1).[18] A key step in the synthesis of 1 is the formation of the chiral amine 
intermediate 2.[19] Two separate methodologies were developed for this step: a transamination 
reaction of the ketone 3 and the asymmetric hydrogenation of the enamide 4.[20] The transaminase 
strategy was ultimately selected and successfully scaled up to a 2.5 kg two-phase process (100 L). 
However, although this method gave fairly high enantioselectivity (97.3 %), the final isolation of the 
amine 2 from the slight excess of amine donor was challenging and involved the derivatization of the 





Scheme 1: The two routes for the production by AstraZeneca of API 1, the focus of this paper. 
 
The hydrogenation route was originally developed as a batch process, and required relatively high 
loadings of the chiral catalyst Rh-(S,S)-EthylDuphos (Scheme 2), and still required the same boc-
derivatization strategy for product extraction. Minimizing the costs and improving the environmental 
footprint of this process represents a real industrial challenge and converting the batch process to a 
heterogeneous continuous technology identified as the method of choice. 
 
Scheme 2: The original Med Chem route[20] involves an asymmetric hydrogenation step which is transposed from batch to 
continuous flow in the present work. 
 
Results and Discussion 
Preliminary experiments, proof-of-concept and optimization 
For our initial studies we selected a commercially available composite of PhosphoTungstic Acid (PTA) 
and aluminum oxide (Alox) as the support. PTA/Alox has been described as being the best performing 
material in previous examples available in the literature.[12a, 16] The Augustine method also provides a 
flexible way to immobilize cationic rhodium catalysts and several ligands can be screened efficiently. 
However, screening was not an important issue in this case because the original AstraZeneca batch 
process already performs with outstanding enantioselectivity using Rh-(S,S)-EthylDuphos as catalyst. 
We therefore kept the same catalyst and focused on identifying the best  strategy for anchoring the 
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catalyst on the PTA/Alox support under continuous flow conditions; initial experiments were carried 
out in ethyl acetate solution (c = 0.009 g/mL) using custom-built high pressure medium scale reactors 
(Figure 2 and ESI). 
Our first trials met with moderate success although the system was already outperforming the batch 
process providing a TON of ca. 235 with high selectivity (> 98 % ee) (ESI). Results were however difficult 
to reproduce, showing stable enantioselectivity but a relatively fast decrease in conversion, suggesting 
catalyst leaching or degradation (see e.g. Figure 3 in the supporting information). Due to the sensitivity 
of the catalyst system towards oxygen and moisture, we modified our reactor set-up by incorporating 
a high-vacuum pump and an argon purge to ensure oxygen and water free conditions in the reaction 
system prior to starting the experiment. Using this modified set-up, more stable catalyst activity was 
achieved with an improved total TON of 935 and high enantioselectivity (> 98 % ee) (see Figure 4 in 
the supporting information). Despite the diluted feed, the maximum TOF of 2.6 min-1 (ESI) is 
comparable to the value of 4.4 min-1 reported by Augustine for the batch hydrogenation of methyl 2-
acetamidoacrylate with Rh/MeDuphos.[12a] In both of our experiments, ICP-MS measurements of the 
collected product mixtures revealed traces of rhodium between 5-15 ppm. 
 
Figure 2: A schematic diagram of the reactor systems used for the development of immobilized rhodium catalyzed 
enantioselective hydrogenation in Nottingham and Aachen. BPR = back pressure regulator, CF = collecting flask, LP = liquid 
pump, M = mixer/moisture trap, MFC = mass flow controller, R = reactor, VP = vacuum pump. 
 
A straightforward “on-line anchoring procedure” was then developed whereby the PTA/Alox support 
was first loaded into the tubular reactor and dehydroxylated at 200 °C under vacuum with regular 
argon flushes. Afterwards, a degassed ethanol solution of the air sensitive organometallic catalyst was 
pumped through the reactor containing the PTA/Alox support, where it is efficiently trapped in-situ by 
ion exchange (see Figure 2 in the supporting information). Following this online anchoring step, the 
hydrogenation of 4 to 5 was carried out in EtOH, a protic solvent already successfully used by Augustine 
(see Figure 6 in the supporting information). This procedure not only simplified operations but also 
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resulted in enhanced catalyst retention with a far lower levels of catalyst leaching than we had 
observed previously (rhodium content in the product mixture ≤ 0.77 ppm) at unchanged TON (ca. 
1000). Visual inspection of the catalyst composite at the end of the reaction showed a non-uniform 
distribution of the catalyst; only the support material at the top of the reactor (entrance) was visibly 
colored. This observation suggests that any possible leaching was offset by a downstream capture of 
the rhodium by the vacant PTA sites. 
Having demonstrated that the Augustine method is well-suited for the continuous-flow hydrogenation 
of 4, efforts were devoted to enhancing the productivity. Intensification of flow processes are typically 
achieved by increasing flowrate, temperature and pressure. In asymmetric hydrogenations, the 
processing window is relatively narrow as increases in temperature and pressure can lead to lower 
enantioselectivity or detachment of the molecular catalyst. Thus, the use of reaction media other than 
EtOAc and EtOH was identified as a key parameter. Thus, the solubility of 4 in ethanol is relatively low 
(0.4 mol/L), thereby counteracting the productivity in terms of space-time-yield. Using ethanol (EtOH 
c = 0.011 g/mL), a maximum TOF value of 13.5 min-1 was attained at full conversion, with an overall 
TON of 1000 similar to that achieved with EtOAc. 
To enhance catalyst productivity, the reaction solvent was switched to tetrahydrofuran (THF), an 
excellent reaction medium for asymmetric hydrogenation.[21]. The solubility of 4 in THF is as high as 
1.0 mol/L allowing a 10-fold increase in concentration (c = 0.11 g/mL) compared with EtOH. Initial 
experiments using a commercially available set-up with a small reactor (Vreactor = 6.0; Vcatalyst bed = 2.7 mL) 
and substrate concentration of 0.2 M showed greatly improved catalyst stability with almost 
quantitative single-pass conversion at enantioselectivities ≥99% ee during the first 13 h on stream and 
a TON of ca. 5000  within 24 h. Overnight a drop in conversion occurred (see Table 2 and Figure 11 in 
the supporting information). 
The productivity was further increased by increasing the substrate concentration to 0.6 M and using a 
reactor system constructed in Aachen[22] comprising a larger reactor (Vreactor = 8.0 mL; Vcatalyst bed = 
3.8 mL); this more productive system gave an overall TON of >5000 in < 7 h on stream with almost full 
conversion and enantioselectivity exceeding 98 % ee. This corresponds to an excellent STY of 520 g/L h 





Figure 3: Continuous flow hydrogenation of 4 with [Rh{(S,S)-EthylDuphos}(cod)]+BF4-/PTA/Al2O3 catalyst and THF as solvent. 
V̇(H2) = 33 mLN/min, V̇(Substrate) = 0.3 mL/min, c(Substrate) = 0.6 M, Vcatalyst bed = 3.8 mL, p = 10 bar, T = 22 °C. 
 
Continuous-flow hydrogenation on a 1 kg/day scale 
Encouraged by successful and reproducible experiments at small scale even with different set-ups and 
different experimentalists in Aachen and Nottingham, it was decided to scale-up the continuous-flow 
hydrogenation of 4 to 5  in Aachen.  A dedicated unit was constructed for its demonstration at 1 Kg/day 
scale, see Figure 4. Further details and operational procedures for this unit are described in ESI. The 
key feature is the exploitation of on-line analysis to discard any sub-standard product that might be 
formed as a result of a malfunction and which, if not removed, would contaminate and  devalue the 
product.  Briefly, the unit consists of dosing systems for liquids and gases (H2), two vertical tubular 
reactors, 150 mL each, connected via a pneumatic valve, so that the reactors can be fed alternately.  
There is a gas/liquid separator downstream of the back-pressure regulator. . On exiting, the liquid 
product stream is directed to a continuous gas chromatograph (GC)-sampler and then on to 2 L 
collection vessels. The on-line GC allows  the product quality to be monitored continuously, as defined 
by both conversion and ee. If the conversion should drop below the defined threshold of 90 % or the 
ee below 98 %, an automatic device will divert the product stream to another collecting vessel so as to 
avoid lowering the  quality  of the material already collected. If the conversion and/or ee values remain 
below the limits for three consecutive GC-measurements, one can  either reduce  all flows 
automatically or to switch to the second reactor containing fresh catalyst without interrupting the 
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continuous-flow experiment.[23] The entire set-up is controlled by software written using NATIONAL 
INSTRUMENTS’ LabView, which permits the set-up and monitoring of all reaction parameters, viewing 
of the analytical data obtained by online chromatography, operation of the pneumatic valve for 
switching between the reactors and to execute a safe shut-down procedure.[24] 
A minimum of 90 % conversion at 98 % enantioselectivity, and a maximum Rh contamination of 
10 ppm were defined as target quality criteria. The asymmetric hydrogenation of 1 kg of 4 was 
performed at 25 °C and 10 bar. The substrate was dissolved in THF (c = 0.11 g/mL) and delivered at 
9 mL/min. H2 was dosed at 870 mLn/min (molar ratio H2 : substrate = 6.75) using a mass flow 
controller. The conversion and selectivity profile including the cumulated TON (tTON) are shown in 
Figure 5. 
The continuous-flow reaction lasted ≈18 h, which was the time needed to flow the whole substrate 
solution (≈10 L) at the chosen flow rate (9 mL/min). The enantiomeric excess throughout the 
continuous reaction ranged between 98.9 % and 98.6 %, above the minimum acceptable limit of 98 %. 
An initial conversion of 99.6 % was detected. After 1 h, the dosage of the substrate was interrupted by 
a ruptured seal on the syringe pump. After replacing the pump with an HPLC-pump, the dosage of the 
substrate was restarted and a conversion >99 % was achieved. After 7 h on stream, there was a 
malfunction of the H2 mass-flow controller (MFC), resulting in a sudden decrease in the H2 flow from 
the initial 900 mLn/min (molar ratio H2 : substrate = 6.5) to only ≈250 mLn/min (molar ratio H2 : 
substrate = 1.8) causing a decrease in the conversion to 75 %. This drop in conversion, well below the 
set-point (90 %), triggered the automation to divert the next product fractions into a separate vessel. 
After the H2 flow problem had been resolved (~30 min later), the conversion reverted to 99 % and 
remained at this level for 3 more hours before slowly decreasing to a minimum of 95 % in the final 
sample. The stable catalyst performance rendered any switch between the reactors unnecessary and 






Figure 4: Scheme of the demonstrator unit. BPR = back pressure regulator; BV = ball valve; CV = check valve; GC = gas 
chromatograph; LP = high pressure syringe pumps; M = mixer; MFC = mass flow controller; P = pressure transducer; PCS = 
automated product collection system, PV = pneumatic three way valve; R = reactor; T = thermocouple. A more complete 
description is given in the ESI.  The argon flush and vacuum pumps are not shown here.   
 
Figure 5: Reaction profile for the continuous-flow asymmetric hydrogenation of 4 on a kilogram scale. 
Conditions: V̇(H2) = 250 mLN/min, V̇(sub) = 9.0 mL/min, c(sub) = 0.6 M (THF), Vcatalyst bed = 147 mL, p = 10 bar, T = 22 °C. 
1-2.5 h: dosage of the substrate interrupted because a pump defect → pump replaced; 
At 7-8 h, there was a sudden drop in conversion due to a malfunction of the H2 mass flowmeter; the system quickly detected 
the problem and diverted the sub-standard product until the problem was fixed and the system re-equilibrated. 
 
Despite the problem with the pump and the malfunction of the H2-MFC, the kilo-scale hydrogenation 
of 4 was realized in less than 18 h with an average conversion of all combined product samples of 
97.6 % at an average selectivity of 98.8 % ee (see ESI). This corresponds to an  STY of up to 400 g/L h 
was obtained with a tTON of ca. 7700 with the catalyst still retaining almost all of its initial activity and 
enantioselectivity even at the end of the campaign. The final work-up consisted of evaporation of the 
THF, to obtain the product as a yellowish solid material (purity ≥ 98%, ee ≥ 99%). Very gratifyingly, the 
ICP-MS analysis of the isolated product revealed a rhodium content below 1 ppm corresponding to 
less than 1%loss of the initial metal-loading of catalyst, very much in line with the stable performance 
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of the catalytic system on a smaller scale. By contrast, the product solution from the original industrial 
batch process contains 1.1 mol% of rhodium, which has to be carefully removed in the work-up 
procedure and requires additional solvents, use of a metal scavenger as well as further manufacturing 
time. 
All the results from  the 1kg scale continuous-flow hydrogenation were well above the predefined 
product specification limits (90 % conversion, 98 % ee, Rh-contamination <10 ppm) a striking 
demonstration of our methodology this-scale. In particular, AstraZeneca have identified the key drivers 
for implementing such an integrated continuous-flow process as the dramatic reduction in Rh-
contamination of the product, and removing the need  for additional solvent, metal scavenging, and 
labor-intensive work-up procedures . A comparison of the continuous flow and the original batch 
process is shown in Table 1 using a traffic light representation. 
 
Table 1: Comparison of the current batch process and the results of the continuous flow experiments (green = better, 
yellow = similar, red = worse). 
  batch  continuous flow  
number of runs needed  6  1  
reactor unit [mL] 660  150  
amount of catalyst needed [mmol] 10.1  0.68  
ee [%] > 98.6  > 98.6  
reaction time [h] 32[a]  18  
process time [h] 64[a] (estim.)  18  
H2-pressure [bar] 4.75  10  
solvent [L] 4 (MeOH)  10 (THF)  
temperature [°C] 25  25  
estimated PMI[b]  4.2  10  
Rh contamination[c]  ppm 260   < 1  
space-time-yield [g/L h] 47  399  
[a] Cumulative values for six batch reactions; [b] Reaction step only;  [c] Rh-content in crude product solution 
 
This comparison clearly favors the continuous-flow system over the batch process. The catalyst loading 
in the flow process is approximately 10 % of the quantity required by the batch methodology, resulting 
in a much more efficient utilization of the precious metal and expensive chiral ligand. The efficiency is 
also reflected by the 10-fold increase in STY in continuous flow. It is also important to note that the 
value  for the PMI (process mass intensity) for the batch process refers only to the reaction step  and 
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do not include  the material–intensive work-up procedure needed in the batch process.  The 
continuous process does not have such a work up stage.  The higher efficiency and suppression of 
metal contaminants are key drivers for a larger scale implementation of this continuous process. Thus, 
according to ICH Q3D guidance on elemental impurities,[25] rhodium is a class 2B metal, meaning that 
manufacturers  must quantify rhodium-content  in the final API if rhodium is used intentionally at any 
stage of the manufacture. The PDE (permitted daily exposure) limit for rhodium via an oral route is 100 
μg/day, and its permitted concentration in drug products, drug substances and excipients is 10 μg/g 
for doses up to 10 g/day.  For parenteral and inhalation, the permitted concentrations are considerably 
lower (1 and 0.1 μg/g respectively). Therefore, controlling the levels of this metal in APIs and 
intermediates in their synthesis is of utmost concern in the pharmaceutical industry and access to a 
methodology, such as ours, that enables this metal to be used in chemical transformations without 
significant contamination of the resulting product or the need for metal scavenging is of great interest. 
 
Conclusions 
The regulations of manufacturing of APIs are vitally important but it does inadvertently result in 
additional costs to pharmaceutical companies. Continuous technologies are now fully integrated 
platforms where quality is controlled by design and operations are automated, thereby offering the 
potential to significantly lower manufacturing costs. At the same time, safety concerns can be reduced 
by the use of smaller volume reactor units. We have shown that the conversion of a batch to a 
continuous-flow process can be achieved using the same commercially-available catalyst as in the 
batch process via a  straightforward and effective immobilization method. Our continuous-flow 
process for the hydrogenation of 4 was optimized and scaled up in a tightly defined time-frame of only 
8 months including the construction time for the production unit at Aachen). Excellent catalyst stability 
and retention in continuous-flow was demonstrated at 1 kg scale resulting in virtually metal-free 
product (Rh content < 1 ppm) with high optical purity (ee >98.6 %) within 18 h. The highly automated 
continuous-flow set-up with on-line analytics developed for this purpose, monitors the product 
specification, selects the appropriate collecting vessel, and even adjusts substrate flow or switches 
reactor cartridge, thus ensuring that the product meets all predefined quality criteria.  As compared to 
the reference batch processes, our continuous flow approach exhibits a much simpler work-up, higher 
efficiency and greater sustainability, all likely to lead to lower manufacturing costs and to a robust and 
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Catching phrase: Pump up the pipe! 
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